{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:58:55Z","timestamp":1788872335429,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.schres.2013.02.030","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T22:04:19Z","timestamp":1363903459000},"page":"224-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia"],"prefix":"10.1016","volume":"146","author":[{"given":"Michael","family":"F. Egan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Gottwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"Harper-Mozley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane","family":"Snavely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Michelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2013.02.030_bb0005","series-title":"(DSM-IV) \u2014 Text Revision","article-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.schres.2013.02.030_bb0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a powerful and practical approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.schres.2013.02.030_bb0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1124\/jpet.110.166876","article-title":"Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease","volume":"336","author":"Brioni","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2013.02.030_bb0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.NMD.0000050937.06332.3C","article-title":"Initial and final work performance in schizophrenia: cognitive and symptom predictors","volume":"191","author":"Bryson","year":"2003","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2013.02.030_bb0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbi020","article-title":"A summary of the FDA-NIMHMATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia","volume":"31","author":"Buchanan","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.02.030_bb0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.biopsych.2010.09.052","article-title":"A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia","volume":"69","author":"Buchanan","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2013.02.030_bb0035","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/schbul\/sbq038","article-title":"The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5years later?","volume":"37","author":"Buchanan","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.02.030_bb0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00213-011-2344-y","article-title":"Additive effects of acholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans","volume":"218","author":"Cho","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2013.02.030_bb0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/156720512800492530","article-title":"Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD","volume":"9","author":"Egan","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.schres.2013.02.030_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevNeurobiol.v14.i1.10","article-title":"Cognitive impairment in schizophrenia is the core of the disorder","volume":"14","author":"Elvev\u00e5g","year":"2000","journal-title":"Crit. Rev. Neurobiol."},{"key":"10.1016\/j.schres.2013.02.030_bb0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/mi.6.2.5","article-title":"Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders","volume":"6","author":"Esbenshade","year":"2006","journal-title":"Mol. Interv."},{"issue":"1","key":"10.1016\/j.schres.2013.02.030_bb0060","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/jpet.104.078402","volume":"313","author":"Fox","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2013.02.030_bb0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.drudis.2009.02.011","article-title":"The histamine H3 receptor as a therapeutic drug target for CNS disorders","volume":"14","author":"Gemkow","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.schres.2013.02.030_bb0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pbb.2010.11.009","article-title":"The treatment of cognitive impairment in schizophrenia","volume":"99","author":"Goff","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.schres.2013.02.030_bb0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u201cright stuff\u201d?","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.02.030_bb0080","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0893-133X(01)00278-0","article-title":"Computerized neurocognitive scanning: I. Methodology and validation in healthy people","volume":"25","author":"Gur","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2013.02.030_bb0085","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0893-133X(01)00279-2","article-title":"Computerized neurocognitive scanning: II. The profile of schizophrenia","volume":"25","author":"Gur","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2013.02.030_bb0090","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jneumeth.2009.11.017","article-title":"A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation","volume":"187","author":"Gur","year":"2010","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.schres.2013.02.030_bb0095","first-page":"218","article-title":"Clinical Global Impressions New Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2013.02.030_bb0100","first-page":"A272","article-title":"The histamine inverse agonist ML-0249 in obstructive sleep apnea patients on CPAP with excessive daytime sleepiness: a randomized, controlled, adaptive crossover study","volume":"33","author":"Herring","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.schres.2013.02.030_bb0105","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.4088\/JCP.11m07178","article-title":"Randomized controlled study of the histamine inverse agonist MK-0249 in adult attention-deficit\/hyperactivity disorder","volume":"73","author":"Herring","year":"2012","journal-title":"J Clin Psychiat"},{"key":"10.1016\/j.schres.2013.02.030_bb0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/ern.09.143","article-title":"Effect of second-generation antipsychotics on cognition: current issues and future challenges","volume":"10","author":"Hill","year":"2010","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.schres.2013.02.030_bb0115","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/clpt.2010.205","article-title":"Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers","volume":"88","author":"Iannone","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2013.02.030_bb0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/JGP.0b013e3182051a7d","article-title":"Computerized neurocognitive test performance in schizophrenia: a lifespan analysis","volume":"20","author":"Irani","year":"2012","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.schres.2013.02.030_bb0125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00213-010-2158-3","article-title":"Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers","volume":"215","author":"James","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2013.02.030_bb0130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.02.030_bb0135","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/schbul\/sbm046","article-title":"How should DSM-V criteria for schizophrenia include cognitive impairment?","volume":"33","author":"Keefe","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.02.030_bb0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.02.030_bb0145","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE schizophrenia trial","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2013.02.030_bb0150","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/13803390500360539","article-title":"The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and realworld functional outcome","volume":"28","author":"Keefe","year":"2006","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.schres.2013.02.030_bb0155","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.02.030_bb0160","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2013.02.030_bb0165","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang","year":"2000","journal-title":"Sankhya Ser. B"},{"key":"10.1016\/j.schres.2013.02.030_bb0170","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1021\/jm8003834","article-title":"Synthesis, structure\u2013activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists","volume":"51","author":"Nagase","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.schres.2013.02.030_bb0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia","volume":"72","author":"Nuechterlein","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.02.030_bb0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/archpsyc.1994.03950020048005","article-title":"Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia","volume":"51","author":"Saykin","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2013.02.030_bb0185","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev.pa.17.040177.001545","article-title":"Histaminergic mechanisms in brain","volume":"17","author":"Schwartz","year":"1977","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.schres.2013.02.030_bb0190","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","article-title":"The histamine H3 receptor: from discovery to clinical trials with pitolisant","volume":"163","author":"Schwartz","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.schres.2013.02.030_bb0195","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0361-9230(91)90126-5","article-title":"Histaminergic neuron system in the brain: distribution and possible functions","volume":"27","author":"Wada","year":"1991","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.schres.2013.02.030_bb0200","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/0269881111398685","article-title":"The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol","volume":"26","author":"Zoethout","year":"2012","journal-title":"J. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413001229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413001229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:24:34Z","timestamp":1760297074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996413001229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":40,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0920996413001229"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2013.02.030","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2013.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}